Immutep (ASX:IMM) reported progress in its study evaluating the effectiveness of IMP761 in treating autoimmune diseases, with the trial now moving to the Part B dose escalation phase, according to a Thursday filing with the Australian bourse.
This follows the completion of Part A of the placebo-controlled, double-blind first-in-human Phase I study, with no safety issues identified during the single-dose administration.
Dosing under Phase B will move from 0.03 mg/kg up to 0.90 mg/kg.
The clinical-stage biotechnology company expects to acquire the study's first safety data before the end of the year.
Immutep's shares inched up 2% in recent trade.
Price (AUD): $0.31, Change: $+0.0050, Percent Change: +1.64%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.